Retatrutide
Triple incretin receptor agonist
An experimental peptide that acts on three hormone receptors. Researchers studied it in phase 2 trials involving weight and blood sugar.
NAD+
Also cited in the literature as Nicotinamide adenine dinucleotide
A coenzyme every cell uses to move energy around. Most published human work studied precursor molecules rather than NAD+ itself.
Regulatory status: Not licensed as a medicine in the United Kingdom. It holds no MHRA marketing authorisation, has no approved indication, and is not approved for human or animal use.
Cell & tissue research
Research stage: Multiple small human trials of precursors published
Cells
Animal studies
Human trials
The research pathway — not every compound has reached human trials. Illustrations are simplified, not study results.
What it is
NAD+ is not a peptide. It is a coenzyme found in all living cells, where it carries electrons in the reactions that release energy from food.
Levels of it fall with age in several published measurements, which is why it became a research interest.
How researchers think it works
Papers described NAD+ as a required partner in energy metabolism and in the activity of repair-related enzymes such as sirtuins and PARPs.
What has research seen in people?
Human trials mostly tested precursor molecules taken by mouth. They reliably raised NAD+ levels measured in blood.
Effects on things people would actually notice — muscle function, insulin sensitivity, inflammation — were small and inconsistent between trials.
Raising a blood marker is not the same as improving health, as several authors pointed out.
Where this material is listed
For laboratory research use only. Not a medicine and not for human or animal use.
Veritide does not sell or supply anything. This links to a third-party UK laboratory supplier; we may earn a commission if you buy through it, at no extra cost to you. Materials are sold for laboratory research use only and are not licensed medicines.
What studies have found
- Human trials mostly tested precursor molecules taken by mouth, such as nicotinamide riboside and nicotinamide mononucleotide. Those trials reliably reported higher NAD+ levels in blood.
- Reported effects on measurable outcomes such as muscle function, insulin sensitivity or inflammation were small and inconsistent between trials.
- Researchers found little published evidence that giving NAD+ itself raises levels inside cells more effectively than precursors.
What we still do not know
- Trials were generally short and small, and their outcome measures varied a great deal.
- Raising a blood marker is not the same as improving health, as several authors noted.
Sources
Related profiles
Mazdutide
Dual GLP-1 / glucagon receptor agonist
An experimental peptide based on a natural gut hormone. Researchers studied it mainly in phase 2 and phase 3 trials in China.
BPC-157
Synthetic pentadecapeptide
A laboratory-made peptide made of 15 amino acids. Almost all published research involved cells or rodents rather than people.